This association further supports the central role of endothelial dysfunction and PAI-1 at the intersection of pulmonary and cardiovascular complications in COVID-19 infection (40, 42), suggesting the targeted inhibition of PAI-1 as a novel therapeutic option to improve outcomes beyond thrombosis in these patients. Here, SERPINE1 is linked to endothelial dysfunction.